Monoclonal antibodies currently in Phase II and III trials for multiple myeloma

被引：10

作者：

Donato, Francesca ^{[1
]}

Gay, Francesca ^{[1
]}

Bringhen, Sara ^{[1
]}

Troia, Rossella ^{[1
]}

Palumbo, Antonio ^{[1
]}

机构：

[1] Univ Turin, Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Myeloma Unit, I-10126 Turin, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2014年 / 14卷 / 08期

关键词：

antibodies; monoclonal; multiple myeloma; LENALIDOMIDE PLUS DEXAMETHASONE; CELL-ACTIVATING FACTOR; LOW-DOSE DEXAMETHASONE; PRECLINICAL MODELS; OPEN-LABEL; HUMAN CD38; GROWTH; COMBINATION; BORTEZOMIB; BEVACIZUMAB;

D O I：

10.1517/14712598.2014.908848

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Introduction: Despite the introduction of novel agents, such as thalidomide, lenalidomide and bortezomib, multiple myeloma (MM) remains an incurable disease and new therapies are needed. mAbs are a new promising anticancer treatment option. Areas covered: This review will focus on mAbs that are currently under evaluation in Phase II and III clinical trials, as single agent and in combination with established treatment options. Expert opinion: mAbs are a new strategy against MM, and they have demonstrated encouraging results in preclinical models. mAbs have a relatively benign side-effect profile and work synergistically with traditional chemotherapies and with immunomodulatory drugs and proteasome inhibitors.

引用

页码：1127 / 1144

页数：18

共 102 条

[1]

[Anonymous], ASH ANN M

[2]

[Anonymous], 2010, CANCER

[3]

[Anonymous], BLOOD

[4] Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma [J].